The Threat of CMV Viremia

CMV viremia, also referred to as CMV infection or reactivation, occurs in 16%-56% (median=30%) of solid organ transplants (SOT) and in 30%-70% of hematopoietic stem cell transplants (HSCT), making it the "troll of transplantation" — and a potentially deadly troll at that, conveying higher risks of graft loss and mortality.1,3,4 And the cost of treatment is significant, with one retrospective study from 2008-2013 with 208 patients showing that more than one incidence of CMV increases the total cost of transplantation by 25%-30% in HSCT.5

Key Challenges of CMV in Transplantation

While there are a number of issues related to CMV in SOT and HSCT recipients, this resource focuses on a small number of critical challenges: refractory and resistant viremia, neutropenia, graft complications, and renal dysfunction.

Key Challenges of CMV in Transplantation

While there are a number of issues related to CMV in SOT and HSCT recipients, this resource focuses on a small number of critical challenges: refractory and resistant viremia, neutropenia, graft complications, and renal dysfunction.

Anatomic Heart Icon.

CMV IN SOLID ORGAN TRANSPLANTATION

Graft loss. Morbidity. Mortality. CMV continues to increase serious complications for solid organ transplant recipients.1

EXPLORE
Cells under a magnifying lens Icon.

CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

While a stem cell transplantation can be lifesaving, it can also expose recipients to the complications of CMV viremia and disease.4

EXPLORE
  1. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900-931.
  2. Duncan MD, Wilkes, DS. Transplant-related Immunosuppression: A Review of Immunosuppression and Pulmonary Infections. Proc Am Thorac Soc. 2005;2(5):449-455.
  3. Stycyzynski J. Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation. Infect Dis Ther. 2018;7(1):1-16.
  4. Cho S, Lee D, Kim H. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int J Mol Sci. 2019;20(2666):1-17.
  5. Robin C, Hémery F, Dindorf C, et al. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients. BMC Infect. Dis. 2017;17(1):1-8.